NovoCure (NVCR) EBITDA (2014 - 2026)

NovoCure has disclosed EBITDA across 13 years of filings, most recently posting -$10.6 million for Q2 2026.

• In Q2 2026, EBITDA rose 73.27% year-over-year to -$10.6 million; the TTM figure through Jun 2026 stood at -$154.4 million (up 10.64% YoY), while the FY2025 annual figure was -$153.8 million, up 9.79% from the prior year.
• EBITDA came in at -$10.6 million for Q2 2026 at NovoCure, up from -$67.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$806000.0 in Q1 2022 to a low of -$67.4 million in Q1 2026.
• Average EBITDA over 5 years is -$40.3 million, with a median of -$40.0 million recorded in 2025.
• Year-over-year, EBITDA plunged 7375.06% in 2023 and soared 73.27% in 2026.
• Over 5 years, EBITDA stood at -$43.0 million in 2022, then slipped by 20.33% to -$51.7 million in 2023, then slipped by 22.41% to -$63.3 million in 2024, then soared by 36.19% to -$40.4 million in 2025, then surged by 73.85% to -$10.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$10.6 million in Q2 2026, -$67.4 million in Q1 2026, and -$40.4 million in Q4 2025.